MRK.DE - Merck Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed price. Currency in EUR
-0.22 (-0.24%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous close90.80
Bid0.00 x 6700
Ask0.00 x 11200
Day's range90.18 - 91.03
52-week range89.04 - 115.20
Avg. volume554,914
Market cap39.318B
PE ratio (TTM)23.61
EPS (TTM)3.84
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Merck Kgaa CFO on Earnings, Consumer Business Options
    Bloomberg Video14 days ago

    Merck Kgaa CFO on Earnings, Consumer Business Options

    Nov.09 -- Merck Kgaa CFO Marcus Kuhnert discusses the company's earnings and performance. He speaks on "Bloomberg Markets."

  • PR Newswire10 days ago

    Merck Receives FDA Approval for New GONAL-f® Prefilled Pen

    Merck, a leading science and technology company, today announced that the company received approval for a new version of GONAL-f® (follitropin alfa injection) prefilled pen from the U.S. Food and Drug Administration (FDA). "Aspiring to be an integrated fertility treatment partner, our strategy focuses on developing user-friendly treatment options for patients," said Luciano Rossetti, Head of Global Research and Development, at the biopharma business of Merck. To date, an estimated 2.5 million babies have been brought to the world with the help of Merck fertility products and services.[2] GONAL-f® is the only gonadotropin that comes in prefilled, ready-to-use pen in the U.S.[3] The new GONAL-f® pen, like its predecessor, enables a fine-tuning of treatment allowing for minimum increments of 12.5 IU to titrate a wide range of doses and precisely target the dosing to patients' needs.[4] In addition, its new design features include an amendment to the dose display window for readability.

  • PR Newswire10 days ago

    Merck and International Diabetes Federation Partner to Help Address Global Type 2 Diabetes Epidemic

    Merck, a leading science and technology company with 60 years of clinical experience in diabetes, today announced its partnership with the International Diabetes Federation (IDF) to implement education and communications activities emphasizing the importance of preventing type 2 diabetes.

  • Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat
    Zacks12 days ago

    Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

    Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

  • Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat
    Zacks14 days ago

    Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat

    Merck KGaA (MKGAF) reports a challenging third-quarter with earnings down year-over-year and sales remaining flat.

  • PR Newswire14 days ago

    NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis

    Merck, a leading science and technology company, today announced that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK) has issued a final appraisal determination (FAD) recommending Cladribine Tablets (MAVENCLAD®) as an option for treating highly active multiple sclerosis* in adults.1 Use of Cladribine Tablets is recommended only if the person has: rapidly evolving severe relapsing-remitting multiple sclerosis, that is, at least two relapses in the previous year and at least one T1 gadolinium-enhancing1 lesion at baseline MRI or relapsing-remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as one relapse in the previous year and MRI evidence of disease activity.

  • Reuters14 days ago

    Merck KGaA tones down outlook but consumer health shines

    By Ludwig Burger FRANKFURT (Reuters) - Germany's Merck KGaA (MRCG.DE) said it was targeting the lower end of its forecast ranges for 2017 results after a stronger euro inflated costs, though double-digit ...

  • What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?
    Zacks15 days ago

    What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

    Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.

  • PR Newswire16 days ago

    Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years

    DARMSTADT, Germany , November 7, 2017 /PRNewswire/ -- New whitepaper from Consumer Health business shine s light on preparing the y oung generation for living 100 healthy years   Whitepaper focuses on ...

  • Reuters - UK Focuslast month

    Reckitt to reshape as sales growth evaporates

    LONDON, Oct (Shenzhen: 000069.SZ - news) 18 (Reuters) - Britain's Reckitt Benckiser (Xetra: A0M1W6 - news) will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.

  • PR Newswire2 months ago

    Merck Invests € 35 Million in its Italian Biotech Manufacturing Site of Bari

    Merck, a leading science and technology company, will invest € 35 million in a new production line for the aseptic filling of biotech medicines under isolator at its manufacturing site of Bari, Italy. The announcement was made as part of an event celebrating the 25th anniversary of the site and its leading role on the science and technology scene in the South Italian region of Apulia. "This investment underpins the importance of the Modugno-Bari production site for our growing Healthcare business," said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.

  • Reuters - UK Focus2 months ago

    Germany's Merck hires JP Morgan to sell consumer health

    FRANKFURT/LONDON, Sept 8 (Reuters) - Germany's Merck KGaA has hired JP Morgan to sell its consumer health business, which includes brands such as Seven Seas vitamins and could be worth around $4.5 billion. The family-controlled drugmaker said on Tuesday it was considering selling the business, whose sales of over-the-counter medicines and vitamin supplements are about $1 billion a year, to help fund research into higher-margin prescription drugs.

  • Reuters - UK Focus3 months ago

    Germany's Merck considers sale of consumer health business

    FRANKFURT/COLOGNE, Sept 5 (Reuters) - Germany's Merck KGaA (LSE: 0O14.L - news) is considering selling its consumer healthcare business which has sales of $1 billion a year to help fund more research into prescription drugs and amid declines in the company's separate liquid crystal business. The company said on Tuesday that to remain competitive the consumer healthcare business would need further investment and therefore it was considering a sale or strategic partnership instead, adding that a review process was at an early stage with a final decision expected to be made early next year. Fully anticipating this, we are preparing strategic options," Belen Garijo, chief executive of Merck's entire Healthcare (Shanghai: 603313.SS - news) division, said in a statement.

  • Business Wire6 months ago

    Merck KGaA, Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Immuno-Oncology Antibody Program

    GENEVA--(BUSINESSWIRE)-- Selexis SA , a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that it has entered an agreement with an affiliate ...

  • Germany’s Merck chooses Israeli deception technology
    CNBC6 months ago

    Germany’s Merck chooses Israeli deception technology

    Dark web intelligence, bio-authorization and even plain old cloud security: Cybersecurity commands a futuristic and slightly dystopian-sounding lexicon.

  • EQS Group7 months ago

    VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies

    DGAP-News: VAXIMM AG / Key word(s): Alliance09.05.2017 / 08:30 The issuer is solely responsible for the content of this announcement. ...

  • Reuters - UK Focus7 months ago

    Gates backs Big Pharma push to wipe out tropical diseases

    The Bill and Melinda Gates Foundation, Western countries and drug companies pledged fresh support on Wednesday to wipe out diseases that blind, disable and disfigure millions of poor in tropical areas each year and urged new donors to join the fight. Some 1.5 billion people, mainly in Asia, Africa and Latin America, are infected with one of 18 neglected tropical diseases known as NTDs, the World Health Organisation (WHO) said.

  • Reuters - UK Focus7 months ago

    Fight against neglected tropical diseases needs Big Pharma push - WHO

    Progress has been made in tackling diseases that blind, disable and disfigure millions of poor in tropical areas each year, but drug companies need to step up donations of medicines, the World Health Organization (WHO) said on Wednesday. One billion people, mainly in Asia, Africa and Latin America, are still treated each year for at least one of 18 neglected tropical diseases known as NTDs, it said. Dengue, onchocerciasis (river blindness), and sleeping sickness are among those carried by mosquitoes or flies that are spreading from rural areas to urban slums, the WHO warned.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes